Stockreport

Zenas BioPharma: Two Late-Stage Catalysts And A $2B InnoCare Deal [Seeking Alpha]

Zenas BioPharma, Inc.  (ZBIO) 
PDF ZBIO's two late-stage candidates, obexelimab and orelabrutinib, drive optimism, with topline Phase 3 INDIGO trial data for obexelimab expected in late 2025. A strong [Read more]